APX2009 and APX2014 are Two Preclinical Retina Candidates

APX2009 and APX2014 are second-generation pre-clinical product candidates analog of APX3330. In mouse models of retinal neovascularization, both APX2009 and APX2014 were effective in decreasing lesion size as well as improved efficacy against the Ref-1 target compared to APX3330. An intravitreal formulation using APX2009 or APX2014 could present itself as an alternative to APX3330’s oral formulation (as published in the Journal of Pharmacology and Experimental Therapeutics).